Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV single-arm study of faricimab in neovascular age-related macular degeneration
ChiCTR2500097936Phase 4Not yet recruiting
- Sponsor
- Chaoju Eye Care
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Chaoju Eye Care. Primary endpoints: Mean change from baseline in best corrected visual acuity and Change from baseline in central retinal thickness. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2500097936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097936.